MedTrace Logo

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

NCT05996848 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-01-09

No results posted yet for this study

Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

Conditions

  • Obesity or Overweight

Interventions

DRUG

Cagrilintide

Participants will receive 2.4 mg cagrilintide subcutaneously.

DRUG

Semaglutide

Participants will receive 2.4 mg semaglutide subcutaneously.

DRUG

Placebo Semaglutide

Participants will receive placebo matched to semaglutide subcutaneously.

DRUG

Placebo Cagrilintide

Participants will receive placebo matched to cagrilintide subcutaneously.

Sponsors & Collaborators

Principal Investigators

  • Clinical Reporting Office (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2025-01-06
Completion
2025-02-22
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05996848 on ClinicalTrials.gov